NCT06836609
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
StatusActive, Not Recruiting
PhasePhase 1/2
SponsorRegeneron Pharmaceuticals
Primary completion (estimated)
At risk: Primary completion moved at least 3 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 16 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Primary and study completion pushed from May 15, 2027 to Aug 17, 2027
- Final enrollment: 118 participants (planned 132)
- Site details revised at 4 of 4 sites
- Minor Study sites: 3 to 4v7
- Notable Phase changed: Phase 1 → Phase 1/2v6
- Minor Study sites: 2 to 3v5
Notable Eligibility criteria expanded, about 17 wordsv4 Show 4 more changesShow less
- Enrollment target: 100 to 132
- Primary and study completion dates: Mar 1, 2027 to May 15, 2027
- Secondary endpoints revised (8)
- Primary endpoints revised (2)
Show 2 earlier versionsHide 2 earlier versions
- Minor Study sites: 1 to 2v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria revised
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Up to 48 Weeks
Severity of TEAEs
Timeframe: Up to 48 Weeks
Secondary (8)
Change in liver fat fraction by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF)
Total concentration of ALN-CIDEB in plasma
Total concentration of potential major metabolite(s) in plasma
Urinary recovery of ALN-CIDEB as a proportion of the dose
Urinary recovery of potential major metabolite(s) as a proportion of the dose
Show 3 moreShow less
Change in Aspartate Aminotransferase (AST)
Change in Alanine Aminotransferase (ALT)
Change in hepatic Cell death-Inducing DNA fragmentation factor alpha-like Effector B (CIDEB) messenger RiboNucleic Acid (mRNA) level
Arms and interventions
Part AExperimental
Randomized per the protocol
Part BExperimental
Randomized per the protocol
Drugs: ALN-CIDEB, Placebo
Sites
4 sites in 2 countries
United Kingdom 2, United States 2